Heinz to use Martek technology

- Last updated on GMT

Related tags: Docosahexaenoic acid, Essential fatty acid, Martek biosciences

Heinz Wattie's, the Australian subsidiary of the giant US food
group, has signed a non-exclusive licensing agreement to use Martek
Biosciences' technology relating to the use of long-chain
polyunsaturated fatty acids in infant formula.

Heinz Wattie's, the Australian subsidiary of the giant US food group, has signed a non-exclusive licensing agreement to use Martek Biosciences' technology relating to the use of long-chain polyunsaturated fatty acids in infant formula.

Under the terms of the deal, which covers Australia, New Zealand, and certain Pacific Islands, Heinz Wattie's will make an initial payment to Martek as well as paying ongoing royalties from the sale of products using Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA) technology.

"Martek is pleased to have Heinz as a partner in supplying better nutrition to infants,"​ said Henry Linsert Jr, chairman and CEO of Martek Biosciences.

Related topics: Suppliers

Follow us

Featured Events

View more

Products

View more

Webinars